Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2022-12-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于公司处置资产的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of an asset disposal transaction by the company Northeast Pharmaceutical Group Co., Ltd. It details the transaction overview, parties involved, asset details, contract contents, and the impact on the company. The document does not contain full financial statements or comprehensive financial analysis but rather provides an update on a specific corporate transaction. It is not an annual report, interim report, earnings release, or audit report. The document is a regulatory announcement about a capital asset disposal transaction, fitting best under Capital/Financing Update (CAP). The document length is 2105 characters, which is consistent with an announcement rather than a full report.
2022-12-07 Chinese
重大诉讼进展公告
Legal Proceedings Report Classification · 95% confidence The document is titled as a "重大诉讼进展公告" which translates to "Major Litigation Progress Announcement." It details the background, recent court rulings, and ongoing legal proceedings involving the company. The content focuses on legal case updates, court decisions, and the company's response including plans to appeal. There are no financial statements, earnings data, or management discussions typical of financial reports. The document is a regulatory announcement about legal proceedings rather than a financial report or other filing type. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 1917 characters, which is sufficient for a detailed legal update but not a full financial report. Hence, the classification is LTR with high confidence.
2022-11-27 Chinese
关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Dongbei Pharmaceutical Group Co., Ltd. regarding its subsidiary receiving a drug registration certificate from the National Medical Products Administration. It details the drug name, specifications, registration details, and the potential impact on the company. The document is short (1345 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed corporate filing. It does not contain financial statements, management discussion, or regulatory certifications. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories like financial reports, management changes, or capital updates.
2022-11-23 Chinese
关于吡拉西坦片获得药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the approval of a drug supplement application by a regulatory authority. It contains no financial data, no mention of financial results, no management or board changes, no voting results, no legal proceedings, no capital changes, and no report attachments. The document is short (903 characters) and serves as a regulatory announcement about a product approval, which fits best under general regulatory announcements that do not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-11-09 Chinese
中国银河证券股份有限公司关于江西方大钢铁集团有限公司要约收购东北制药集团股份有限公司之2022年三季度持续督导意见暨持续督导总结报告
M&A Activity Classification · 95% confidence The document is titled as a "2022 Third Quarter Continuous Supervision Opinion and Summary Report" by China Galaxy Securities Co., Ltd. regarding a tender offer acquisition of Northeast Pharmaceutical Group Co., Ltd. by Jiangxi Fangda Steel Group Co., Ltd. It details the ongoing supervision during the tender offer period, compliance with laws and regulations, fulfillment of public commitments, and future plans related to the acquisition. The content focuses on the monitoring and advisory role of the financial advisor during the acquisition process, including compliance and governance aspects, rather than presenting financial statements or earnings data. This type of document is related to merger and acquisition activity, specifically continuous supervision and reporting on a tender offer. Therefore, the most appropriate classification is M&A Activity (Code: TAR). The document length (5595 characters) and detailed content support it being a substantive report rather than a brief announcement or certification.
2022-11-09 Chinese
关于2022年限制性股票激励计划预留部分授予登记完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding the completion of the registration of a reserved portion of a 2022 restricted stock incentive plan. It details the number of shares granted, the price, the recipients, the approval process, and related corporate governance steps. It does not contain financial statements or comprehensive financial performance data but rather focuses on the stock incentive plan implementation and related share capital changes. This type of document is an announcement about a capital change related to share issuance under an incentive plan, not a full financial report or management discussion. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is over 5,000 characters and contains detailed information about the share issuance, not just a brief notice or a certification, so it is not RPA or RNS.
2022-11-03 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.